259 related articles for article (PubMed ID: 27315356)
1. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
Lim SH; Sun JM; Choi YL; Kim HR; Ahn S; Lee JY; Lee SH; Ahn JS; Park K; Kim JH; Cho BC; Ahn MJ
Cancer; 2016 Oct; 122(19):3024-31. PubMed ID: 27315356
[TBL] [Abstract][Full Text] [Related]
2. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
[TBL] [Abstract][Full Text] [Related]
3. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
4. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.
Göke F; Franzen A; Menon R; Goltz D; Kirsten R; Boehm D; Vogel W; Göke A; Scheble V; Ellinger J; Gerigk U; Fend F; Wagner P; Schroeck A; Perner S
Chest; 2012 Oct; 142(4):1020-1026. PubMed ID: 22499828
[TBL] [Abstract][Full Text] [Related]
5. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
Lim SM; Chung WY; Nam KH; Kang SW; Lim JY; Kim HG; Shin SH; Sun JM; Kim SG; Kim JH; Kang CW; Kim HR; Cho BC
Eur J Cancer; 2015 Aug; 51(12):1588-95. PubMed ID: 26070683
[TBL] [Abstract][Full Text] [Related]
6. A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
Paik PK; Shen R; Berger MF; Ferry D; Soria JC; Mathewson A; Rooney C; Smith NR; Cullberg M; Kilgour E; Landers D; Frewer P; Brooks N; André F
Clin Cancer Res; 2017 Sep; 23(18):5366-5373. PubMed ID: 28615371
[No Abstract] [Full Text] [Related]
7. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
Kim HR; Kim DJ; Kang DR; Lee JG; Lim SM; Lee CY; Rha SY; Bae MK; Lee YJ; Kim SH; Ha SJ; Soo RA; Chung KY; Kim JH; Lee JH; Shim HS; Cho BC
J Clin Oncol; 2013 Feb; 31(6):731-7. PubMed ID: 23182986
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC).
Guo Q; Sun Y; Yu S; Bai H; Zhao J; Zhuo M; Wang J
Thorac Cancer; 2017 Mar; 8(2):73-79. PubMed ID: 28008744
[TBL] [Abstract][Full Text] [Related]
10. FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer.
Flockerzi FA; Roggia C; Langer F; Holleczek B; Bohle RM
Virchows Arch; 2018 May; 472(5):759-769. PubMed ID: 29270870
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
[TBL] [Abstract][Full Text] [Related]
12. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
Musolino A; Campone M; Neven P; Denduluri N; Barrios CH; Cortes J; Blackwell K; Soliman H; Kahan Z; Bonnefoi H; Squires M; Zhang Y; Deudon S; Shi MM; André F
Breast Cancer Res; 2017 Feb; 19(1):18. PubMed ID: 28183331
[TBL] [Abstract][Full Text] [Related]
13. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
Kim HR; Kang HN; Shim HS; Kim EY; Kim J; Kim DJ; Lee JG; Lee CY; Hong MH; Kim SM; Kim H; Pyo KH; Yun MR; Park HJ; Han JY; Youn HA; Ahn MJ; Paik S; Kim TM; Cho BC
Ann Oncol; 2017 Jun; 28(6):1250-1259. PubMed ID: 28460066
[TBL] [Abstract][Full Text] [Related]
14. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.
Tran TN; Selinger CI; Kohonen-Corish MRJ; McCaughan BC; Kennedy CW; O'Toole SA; Cooper WA
Lung Cancer; 2013 Sep; 81(3):462-467. PubMed ID: 23806793
[TBL] [Abstract][Full Text] [Related]
17. An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.
Morgensztern D; Karaseva N; Felip E; Delgado I; Burdaeva O; Dómine M; Lara P; Paik PK; Lassen U; Orlov S; Trigo J; Shomova M; Baker-Neblett K; Vasquez J; Wang X; Yan L; Mitrica I; DeYoung MP; Garrido P
Lung Cancer; 2019 Oct; 136():74-79. PubMed ID: 31446228
[TBL] [Abstract][Full Text] [Related]
18. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
Wynes MW; Hinz TK; Gao D; Martini M; Marek LA; Ware KE; Edwards MG; Böhm D; Perner S; Helfrich BA; Dziadziuszko R; Jassem J; Wojtylak S; Sejda A; Gozgit JM; Bunn PA; Camidge DR; Tan AC; Hirsch FR; Heasley LE
Clin Cancer Res; 2014 Jun; 20(12):3299-309. PubMed ID: 24771645
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma.
Craddock KJ; Ludkovski O; Sykes J; Shepherd FA; Tsao MS
J Thorac Oncol; 2013 Nov; 8(11):1371-7. PubMed ID: 24077455
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.
Cihoric N; Savic S; Schneider S; Ackermann I; Bichsel-Naef M; Schmid RA; Lardinois D; Gugger M; Bubendorf L; Zlobec I; Tapia C
Br J Cancer; 2014 Jun; 110(12):2914-22. PubMed ID: 24853178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
